- Home
- GANX vs DTIL Comparison
GANX vs DTIL Comparison
Compare GANX & DTIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GANX
- DTIL
- Stock Information
- Founded
- GANX 2017
- DTIL 2006
- Country
- GANX United States
- DTIL United States
- Employees
- GANX N/A
- DTIL N/A
- Industry
- GANX Biotechnology: Pharmaceutical Preparations
- DTIL Biotechnology: Pharmaceutical Preparations
- Sector
- GANX Health Care
- DTIL Health Care
- Exchange
- GANX Nasdaq
- DTIL Nasdaq
- Market Cap
- GANX 45.8M
- DTIL 56.2M
- IPO Year
- GANX 2021
- DTIL 2019
- Fundamental
- Price
- GANX $1.95
- DTIL $5.02
- Analyst Decision
- GANX Strong Buy
- DTIL Strong Buy
- Analyst Count
- GANX 5
- DTIL 2
- Target Price
- GANX $8.20
- DTIL $47.00
- AVG Volume (30 Days)
- GANX 314.5K
- DTIL 161.1K
- Earning Date
- GANX 05-13-2025
- DTIL 05-15-2025
- Dividend Yield
- GANX N/A
- DTIL N/A
- EPS Growth
- GANX N/A
- DTIL N/A
- EPS
- GANX N/A
- DTIL 1.04
- Revenue
- GANX N/A
- DTIL $68,696,000.00
- Revenue This Year
- GANX N/A
- DTIL N/A
- Revenue Next Year
- GANX N/A
- DTIL $30.20
- P/E Ratio
- GANX N/A
- DTIL $4.95
- Revenue Growth
- GANX N/A
- DTIL 40.98
- 52 Week Low
- GANX $0.89
- DTIL $3.61
- 52 Week High
- GANX $3.19
- DTIL $13.44
- Technical
- Relative Strength Index (RSI)
- GANX 54.26
- DTIL 51.79
- Support Level
- GANX $1.85
- DTIL $5.00
- Resistance Level
- GANX $2.27
- DTIL $5.97
- Average True Range (ATR)
- GANX 0.16
- DTIL 0.35
- MACD
- GANX 0.02
- DTIL -0.02
- Stochastic Oscillator
- GANX 59.17
- DTIL 29.90
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.